Trial Profile
Open-label study to assess safety, pharmacokinetics and exposed dose of NMK20 in healthy Japanese male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Folic acid (Primary) ; Technetium Tc99m etarfolatide (Primary)
- Indications Non-small cell lung cancer; Pituitary cancer; Renal cancer
- Focus Adverse reactions
- Sponsors Nihon Medi-Physics
- 17 Jun 2016 New trial record